Researchers explored the risk-benefit ratios of two major mesothelioma chemotherapy regimens: pemetrexed + cisplatin and pemetrexed + carboplatin. They found one of the combinations to pose a lower risk of side effects, making it more appropriate for older patients or patients with a low performance status.
↧